检索结果-南通市图书馆

The effect of long-term traditional Chinese medicine treatment on disease-free survival of postoperative stage I-III lung cancer patients:a retrospective cohort study

引用

Traditional Medicine Research 2019年第2期4卷 91-98页

作者： Su-Tong Liu Su-Fang Zhang Kai-Qi Su Ying-Bin Luo Zhi-Hong Fang Yuan Fang Jing Xu Jian-Chun Wu Yan Li Department of Oncology Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai China Department of Traditional Chinese and Western Medicine Shanghai Pulmonary Hospital of Tongji University School of Medicine Shanghai China. Shanghai University of Traditional Chinese Medicine Shanghai China

Objective:Traditional Chinese medicine(TCM)has been extensively used as one of popular alternative therapies for several ***,it remains unclear whether TCM treatment is associated with longer survival in lung cancer *** this study,we explored the effect of long-term TCM treatment on patients with different stages of lung ***:All information of lung cancer patients with stage I-III disease from January 2007 to September 2015 was collected for this retrospective cohort *** who were treated with TCM after surgery were divided into TCM group and the others were into the non-TCM group(control group).All patients were regularly followed up by clinic appointment or phone,and all survival data were collected from databases after the last follow-up in October ***:A total of 575 patients were included in this study,with 299 patients in the TCM group and 276 in the control *** all patients,5-year disease-free survival(DFS)was 62.2% in TCM group and 42.1% in the control group,and 6-year DFSs were 51.8% and 35.4%,respectively(HR=0.51,95% CI:0.40 to 0.66,log-rank P≤0.001).For patients with stage I,5-year DFSs were 83.7%(TCM group)and 57.5%(control group)and 6-year DFSs were 73.7% and 51.9%,respectively(HR=0.30,95% CI:0.18 to 0.50,log-rank P≤0.001).For patients with stage II in the TCM group and the control group,5-year DFSs were 59.4% and 17.6% and 6-year DFSs were 44.7% and 17.6%,respectively(HR=0.31,95% CI:0.19 to 0.52,log-rank P≤0.001),and for patients with stage III,5-year and 6-year DFSs in the TCM group were 18.7% and 12.5% compared with 28.4% and 20.3% in the control group(HR=1.06,95% CI:0.72 to 1.56,log-rank P=0.76).Conclusions:This study demonstrated that long-term TCM treatment as an adjuvant therapy is able to improve the DFS of postoperative stage I-III lung cancer patients,especially in patients with stage I and II ***,these observational findings need being validated by large sample randomized control

关键词： Traditional Chinese medicine Lung cancer disease-free survival Retrospective study Cohort study

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Long-term disease-free survival in a dog with appendicular osteosarcoma

引用

畜牧与兽医 2012年第S2期44卷 62-62页

作者： Kumiko Ishigaki Kazushi Asno Yoshiya Yoshida Rikiya Nishimura Hiromi Aoki Gentoku Iida Orie Yoshida Mamiko Seki Kenji Teshima Kazuya Edamura Animal Medical Center Nihon University Laboratory of Veterinary Surgery Department of Veterinary Medicine College of Bioresource SciencesNihon University SHIMA Laboratories Co. LTD Laboratory of Comprehensive Veterinary Clinical Studies Department of Veterinary Medicine College of Bioresource SciencesNihon University

Postoperative prognosis is generally poor even with adjuvant chemotherapy in dogs with an appendicular osteosarcoma. The purpose of this report was to present the long-term disease-free survival time in a dog with appendicular osteosarcoma receiving amputation,adjuvant chemotherapy and adoptive immunotherapy. A 12-year-old spayed Golden retriever was referred to our hospital with a suspicion of osteosarcoma in right distal radius. The patient underwent the computed tomography (CT) and incisional biopsy on the next day after the first presentation. The CT revealed the osteolysis in the right distal radius and no metastases in the lungs and lymph nodes. The histopathologic diagnosis was made as an osteosarcoma. On the 13th day after,the patient underwent right forelimb amputation. Six doses of carboplatin (250 mg / m2) were postoperatively administered every 3 weeks. The intravenous infusion of lymphokine-activated killer (LAK) cells suspension was performed every 3 ~ 4 weeks after the adjuvant chemotherapy. At the time of our writing this abstract (on the 880thday after the first presentation),no recurrences and metastases were observed after the 32 transfers of LAK cells. In canine appendicular osteosarcoma,some reports have described that postoperative median survival times were 235 ~ 540 d with adjuvant chemotherapy. In our report,the disease free interval and survival time were prolonged compared with the previous reports. We strongly believed that early diagnosis and surgical intervention and adoptive immunotherapy had a great impact on the improvement of survival time in canine appendicular osteosarcoma.

关键词： adoptive immunotherapy adjuvant chemotherapy appendicular osteosarcoma,dog long-term disease-free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study

引用

Chinese Journal of Integrative Medicine 2019年第11期25卷 812-819页

作者： WANG Xue-qian ZHANG Ying HOU Wei WANG Ying-tian ZHENG Jia-bin LI Jie LIN Li-zhu JIANG Yi-lan WANG Shen-yu XIE Ying ZHANG Hong-liang SHU Qi-jin LI Ping WANG Wei YOU Jian-liang LI Ge LIU Jie FAN Hui-ting ZHANG Mei-ying LIN Hong-sheng Department of Oncology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijing (100053)China Department of Oncology Wuxi Hospital of Traditional Chinese MedicineWuxiJiangsu Province (214000)China Department of Oncology Dalian Hospital of Traditional Chinese MedicineDalianLiaoning Province (116000)China Department of Oncology The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou (510000)China Department of Oncology Hunan Academy of Traditional Chinese Medicine Affiliated HospitalChangsha (410000)China Department of Integrated TCM & Western Medicine Cancer Hospital of Liaoning ProvinceShenyang (110000)China Department of Traditional Chinese Medicine Cancer Hospital of Shanxi ProvinceTaiyuan (030000)China Department of Oncology The Xinjiang Uygur Autonomous Region Traditional Chinese Medicine HospitalUrumqi (830000)China Department of Oncology Zhejiang Provinee Traditional Chinese Medicine HospitalHangzhou (310000)China Oncology Department of Traditional Chinese Medicine Anhui Provincial HospitalHefei (230000)China Oncology Department of Traditional Chinese Medicine Chongqing Cancer HospitalChongqing (400000)China

Objective:To evaluate the association between Chinese medicine(CM)therapy and disease-free survival(DFS)outcomes in postoperative patients with non-small cell lung cancer(NSCLC).Methods:This multiple-center prospective cohort study was conducted in 13 medical centers in *** with stage I,II,or IDA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network(NCCN)guidelines were *** recruited patients were divided into a CM treatment group and a control group according to their *** in the CM treatment group received continuous CM therapy for more than 6 months or until disease *** in the control group received CM therapy for less than 1 ***-up was 8nducted over 3 *** primary outcome was DFS,with recurrence/metastasis rates as a secondary ***:Between May 2013 and August 2016,503 patients were enrolled into the cohort;266 were classified in the CM treatment group and 237 in the control *** for covariates,high exposure to CM was associated with better DFS[hazard ratio(HR)=0.417,95%confidential interval(Cl):0.307-0.567)].A longer duration of CM therapy(6-12 months,12-18 months,>24 months)was associated with lower recurrence and metastasis rates(HR=0.225,0.119 and 0.083,respectively).In a subgroup exploratory analysis,CM therapy was also a protective factor of cancer recurrence and metastasis in both stage n-MA(HR=0.50,95%Cl:0.37-0.67)and stage IDA NSCLC postoperative patients(HR=0.48,95%Cl:0.33-0.71),DFS was even longer among CM treatment group ***:Lon ger duration of CM therapy could be 8nsidered a protective factor of cancer recurrence and *** treatment is associated with improving survival outcomes of postoperative NSCLC patients in China.

关键词： Chinese medicine non-small cell lung cancer postoperative care cohort study disease-free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind randomized controlled clinical trial

引用

Journal of Traditional Chinese Medicine 2020年第1期40卷 103-111页

作者： Li Yifan Li Juan Fan Bifa Wang Yitong Jiang Juling Zhang Zhenhua Wang Xinxing Lu Wenping Department of Oncology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijing 100053China Department of Graduate School Beijing University of Chinese MedicineBeijing 100029China Department of Graduate School China Academy of Chinese Medical SciencesBeijing 100700China Department of Pain China-Japan Friendship HospitalBeijing 100029China

OBJECTIVE:To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD)on patients with advanced epithelial ovarian cancer(EOC).METHODS:All 330 enrolled participants diagnosed with stageⅢc EOC were randomly divided into two groups that received YHJD or a *** primary end point was health-related quality of life(HRQL)measured by the functional assessment of cancer therapy-ovary cancer(FACT-O)*** secondary end point was progression-free survival(PFS).RESULTS:A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,*** 6 months of treatment,YHJD increased physical wellbeing(PWB),functional wellbeing(FWB),additional concerns(AC),and the trial outcome index(TOI)(P<0.05)by various degrees compared with the *** also had notable advantages over the placebo at 3 and 6 months in terms of PWB,FWB,AC(P<0.05),and TOI(P<0.01).In addition,YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months,P<0.05).No adverse events were ***:YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stageⅢc EOC patients.

关键词： Ovarian neoplasms Quality of life disease-free survival Yiqi Huoxue Jiedu decoction Randomized controlled trial

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage Ⅲ colon cancer

引用

Journal of Traditional Chinese Medicine 2019年第2期39卷 251-257页

作者： Li Kai Liu Rui Xu Guangzhong Zhang Weihua Liu Chen Zhu Bin Hua Baojin Feng Xingzhong Department of oncological surgery Beijing Shijitan Hospital Capital Medical University Department of oncology Guang'anmen Hospital China Academy of Chinese Medical Sciences Traditional Chinese Medicine Beijing Shijitan Hospital Capital Medical University

OBJECTIVE: To investigate the effect of a modified Banxia Xiexin decoction(MBXD) plus chemotherapy on postoperative adverse reaction in patients with stage Ⅲ colon cancer in patients whose symptoms were identified as cold-heat complicated pattern in terms of the theory of Traditional Chinese Medicine(TCM).METHODS: A prospective non-randomized control study of patients with stage Ⅲ colon cancer in Beijing Shijitan Hospital and Guang'anmen Hospital between January 2012 and December 2013. A total of 80 patients were divided into experimental group(MBXD + chemotherapy) and control group(chemotherapy). The adverse reactions, life quality and disease-free survival(DFS) were compared between the two ***: The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group(P < 0.05). Life quality was improved in 24 vs 14 cases, stabilized in 9 vs14 cases whereas decreased in 2 vs 15 cases in experimental group and control group, respectively(P < 0.05). The average DFS was 22.371 months in experimental group, while 13.932 months in control group(P < 0.05).CONCLUSION: MBXD combined with chemotherapy may significantly relieve clinical symptoms, reduce chemotherapy associated adverse effects, improve life quality, and prolong DFS of patients with stage Ⅲ colon cancer(cold-heat complicated pattern).

关键词： Colonic neoplasms Drug therapy Signs and symptoms Quality of life disease-free survival Syndromes and signs Banxia Xiexin decoction

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients

引用

Cancer Biology & Medicine 2019年第2期16卷 350-360页

作者： Yuhan Zhang Shuaibing Wang Beibei Yang Su Lu Yiyi Du Hong Liu The Second Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital/ National Clinical Research Center for Cancer/ Key Laboratory of Cancer Prevention and Therapy Tianjin/ Tianjin's Clinical Research Center for Cancer/ Key Laboratory of Breast Cancer Prevention and Therapy Tianjin Medical University Ministry of Education Tianjin 300060 China Oncology Department China National Petroleum Corporation Central Hospital Langfang 065000 China

Objective: To examine the efficacy and safety of a sequential combination of chemotherapy and autologous cytokine-induced killer(CIK) cell treatment in triple-negative breast cancer(TNBC) ***: A total of 294 post-surgery TNBC patients participated in the research from January 1, 2009 to January 1, 2015. After adjuvant chemotherapy, autologous CIK cells were introduced in 147 cases(CIK group), while adjuvant chemotherapy alone was used to treat the remaining 147 cases(control group). The major endpoints of the investigation were the disease-free survival(DFS) and overall survival(OS). Additionally, the side effects of the treatment were ***: In the CIK group, the DFS and OS intervals of the patients were significantly longer than those of the control group(DFS:P = 0.047;OS: P = 0.007). The multivariate analysis demonstrated that the TNM(tumor-node-metastasis) stage and adjuvant CIK treatment were independent prognostic factors for both DFS [hazard ratio(HR)= 0.520, 95% confidence interval(CI):0.271-0.998, P = 0.049;HR = 1.449, 95% CI:1.118-1.877, P = 0.005, respectively] and OS(HR=0.414, 95% CI:0.190-0.903, P = 0.027;HR= 1.581, 95% CI:1.204-2.077, P = 0.001, respectively) in patients with TNBC. Additionally, longer DFS and OS intervals were associated with increased number of CIK treatment cycles(DFS: P = 0.020;OS: P = 0.040). The majority of the patients who benefitted from CIK cell therapy were relatively early-stage TNBC ***: Chemotherapy in combination with adjuvant CIK could be used to lower the relapse and metastasis rate, thus effectively extending the survival time of TNBC patients, especially those at early stages.

关键词： Immunotherapy triple-negative breast cancer cytokine-induced killer cell prognosis disease-free survival overall survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy

引用

Cancer Biology & Medicine 2018年第4期15卷 415-424页

作者： Jingjing Wu Peng Zhu Zhanguo Zhang Bixiang Zhang Chang Shu Lin Chen Renjie Feng Abdoul aziz Mba'nbo koumpa Ganxun Li Qianyun Ge Department of Hepatic Surgery Center Tongji Hospital of Tongji Medical College of Huazhong University of Science and TechnologyWuhan 430030China Department of Neurology Tongji Hospital of Tongji Medical College of Huazhong University of Science and TechnologyWuhan 430030China

Objective:Spontaneous hepatocellular carcinoma(HCC)rupture can be fatal,and hepatic resection could achieve a favorable long-term survival among all strategies of tumor ***,there is no available prognostic scoring system for patients with ruptured HCC who underwent partial ***:From January 2005 to May 2015,129 patients with spontaneous HCC rupture underwent partial *** clinical data were collected and *** risk factors affecting overall survival(OS)were used to develop the new scoring ***’s C statistics,Akaike information criterion(AIC),the relative likelihood,and the log likelihood ratio were calculated to measure the homogeneity and discriminatory ability of a prognostic ***:In the multivariable Cox regression analysis,three factors,including tumor size,preoperativeα-fetoprotein level,and alkaline phosphatase level,were chosen for the new tumor-associated antigen(TAA)prognostic scoring *** 1-year OS rates were 88.1%,43.2%,and 30.2%for TAA scores of 0–5 points(low-risk group),6–9 points(moderate-risk group),and 10–13points(high-risk group),*** TAA scoring system had superior homogeneity and discriminatory ability(Harrell’s C statistics,0.693 vs.0.627 and 0.634;AIC,794.79 vs.817.23 and 820.16;relative likelihood,bothdisease-free survival(DFS).Conclusions:The new prognostic scoring system is simple and effective in predicting both OS and DFS of patients with spontaneous ruptured HCC.

关键词： Spontaneous rupture prognostic scoring system homogeneity discriminatory ability overall survival disease-free survival hepatocellular carcinoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Correlation of radiotherapy with prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping

引用

Chinese Journal of Cancer Research 2019年第3期31卷 471-480页

作者： Xiangcheng Zhi Xiaonan Yang Teng Pan Jingjing Liu Xiao Chen Liping Lou Zhendong Shi Jin Zhang Department of Breast Cancer Tianjin Medical University Cancer Institute & Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin’s Clinical Research Cancer for Cancer

Objective: The present study examined the effect of radiotherapy on recurrence and survival in elderly patients with hormone receptor-positive early breast ***: A retrospective analysis of 327 patients aged ≥65 years, with stage I-II, hormone receptor-positive breast cancer who underwent breast-conserving surgery and received endocrine therapy(ET) or radiotherapy plus endocrine therapy(ET+RT) was performed. Both groups were divided into luminal A type and luminal B type subgroups. Evaluation criteria were 5-year disease-free survival(DFS), local relapse rate(LRR), overall survival(OS), and distant metastasis rate(DMR).Results: There were significant differences in 5-year DFS [hazard ratio(HR)=1.59, 95% confidence interval(95% CI), 1.15-2.19;P=0.005] and LRR(HR=3.33, 95% CI, 1.51-7.34;P=0.003), whereas there were no significant differences in OS and DMR between ET group and ET+RT group. In luminal A type, there was no significant difference in 5-year DFS, LRR, OS and DMR between ET group and ET+RT group. In luminal B type,there were statistically significant differences in 5-year DFS(HR=2.19, 95% CI, 1.37-3.49;P=0.001), LRR(HR=5.45, 95% CI, 1.65-17.98;P=0.005), and OS(HR=1.75, 95% CI, 1.01-3.05;P=0.048) between ET group and ET+RT group. In the ET group, there were significant differences between luminal A type and luminal B type in5-year DFS(HR=1.84, 95% CI, 1.23-2.75;P=0.003) and OS(HR=1.76, 95% CI, 1.07-2.91;P=0.026).Conclusions: After breast-conserving surgery, radiotherapy can reduce the LRR and improve the DFS and OS of luminal B type elderly patients, whereas luminal A type elderly patients do not benefit from *** radiotherapy, luminal A type patients have better DFS and OS than luminal B type patients.

关键词： Breast-conserving surgery disease-free survival endocrine therapy hormone receptor-positive overall survival radiotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy

引用

World Journal of Gastrointestinal Oncology 2019年第12期11卷 1172-1181页

作者： Ya Zeng Wen Yu Qi Liu Wei-Wei Yu Zheng-Fei Zhu Wei-Xin Zhao Jun Liu Jia-Ming Wang Xiao-Long Fu Yuan Liu Xu-Wei Cai Department of Radiation Oncology Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Department of Radiation Oncology Fudan University Shanghai Cancer CenterShanghai 200030China Department of Radiation Oncology Shanghai Jiao Tong University Affiliated Shanghai Sixth People’s HospitalShanghai 200030China Department of Statistics Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China

BACKGROUND There has been no study comparing the difference in the failure patterns between patients with or without postoperative radiotherapy(PORT)after esophagectomy for pT3-4N0-3M0 esophageal squamous cell carcinoma(ESCC).AIM To investigate the difference in the failure patterns of stage pT3-4N0-3M0 ESCC patients with or without *** Patients with stage pT3-4N0-3M0 ESCC,who underwent surgery with or without PORT,were enrolled in this *** primary endpoint was to investigate the difference in the failure patterns between patients with or without PORT after *** secondary endpoint was to estimate whether patients with stage pT3-4 ESCC could achieve a disease-free survival(DFS)advantage after receiving adjuvant *** analyses were performed by the Kaplan-Meier method,Cox regression model,and Chi-squared test or Fisher’s exact *** In total,230 patients with stage pT3-4N0-3M0 ESCC were included in this ***-six patients who received PORT were screened from a prospective cohort(S+R arm).And 174 patients involving surgery alone were retrospectively selected from July 2006 to October 2014(S arm).There were no significant differences in the clinical or pathological characteristics of patients between the two arms,except for tumor location(P=0.031).The failure patterns between the two arms were significantly different(P<0.001).Patients in the S arm had a significantly higher proportion of locoregional recurrence and a lower proportion of distant metastasis than those in the S+R arm(92.0%vs 35.7%,P<0.001 and 19.0%vs 75.0%,P<0.001,respectively).The difference in the median DFS between the two arms was statistically significant(12.7 vs 8 mo,P=0.048).Univariate analysis and multivariate analysis both demonstrated that the number of lymph node metastases≥3(HR=0.572,95% CI:0.430-0.762,P<0.001)was an independent poor prognostic factor for DFS in patients with stage pT3-4N0-3M0 *** PORT could improve DFS and local c

关键词： Esophageal squamous cell carcinoma Postoperative radiotherapy Failure patterns disease-free survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Recurrence and survival after surgery for pancreatic cancer with or without acute pancreatitis

引用

World Journal of Gastroenterology 2019年第39期25卷 6006-6015页

作者： Qian Feng Cheng Li Sheng Zhang Chun-Lu Tan Gang Mai Xu-Bao Liu Yong-Hua Chen Department of Pancreatic Surgery West China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina Rehabilitation Medicine Center West China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina Department of Hepatobiliary Surgery The First Affiliated Hospital of Xinxiang Medical UniversityXinxiang 453100Henan ProvinceChina Department of Hepatobiliary Surgery Deyang People's HospitalDeyang 618000Sichuan ProvinceChina

BACKGROUND In pancreatic cancer,acute pancreatitis(AP)is a serious morbidity,but its negative effect on long-term outcomes remains to be *** To investigate the effects of AP on the tumor recurrence pattern of pancreatic ductal adenocarcinoma(PDAC)and tumor-specific *** The medical records of 219 patients with curative pancreatectomy for pancreatic cancer at the Pancreatic Surgery Center of West China Hospital from July 2012 to December 2016 were analyzed *** severity of acute pancreatitis was classified according to the Atlanta classification of *** patient demographics and tumor characteristics were *** recurrence was defined as a relapse within 12 mo after *** and disease-free survival and recurrence patterns were *** acute pancreatitis was excluded because its negative effects can be *** Early recurrence in AP group was significantly higher than in non-AP group(71.4%vs 41.2%;P=0.009).Multivariate analysis of postoperative early recurrence showed that moderate or severe AP was an independent risk factor for an early recurrence[odds ratio(OR):4.13;95%confidence interval(CI):1.41-12.10;P=0.01].The median time to recurrence was shorter in patients with AP than in those without(8.4 vs 12.8 mo;P=0.003).Multivariate analysis identified AP as an independent prognostic factor for overall survival[relative risk(RR):2.35;95%CI:1.45-3.83]and disease-free survival(RR:2.24;95%CI:1.31-3.85)in patients with *** Patients with moderate or severe acute pancreatitis developed recurrences earlier than those *** or severe AP is associated with shorter overall and disease-free survival of patients with PDAC.

关键词： Acute pancreatitis Pancreatic ductal adenocarcinoma Recurrence Prognosis Overall survival disease-free survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：